Skip to main
COGT
COGT logo

Cogint (COGT) Stock Forecast & Price Target

Cogint (COGT) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences Inc. is strategically positioned for significant growth, with 2025 anticipated as a landmark year that may attract merger and acquisition interest. Positive outcomes from the APEX and PEAK trials, along with favorable results from the SUMMIT trial, bolster the potential of bezuclastinib to establish itself as a significant player across multiple malignancies. The company's focus on precision therapies targeting genetically defined diseases, including Systemic Mastocytosis and advanced gastrointestinal stromal tumors, underlines its commitment to improving patient outcomes and enhances its market potential.

Bears say

Cogent Biosciences Inc. has projected a significantly negative financial outlook, with anticipated losses of $2.28 per share for the full year 2025. The company faces multiple risks that could further exacerbate its financial situation, including negative clinical data, slower-than-expected development timelines, and potential setbacks in both later-stage and earlier-stage trials. Additionally, concerns regarding regulatory approvals and commercial success highlight ongoing challenges, contributing to overall uncertainty about future performance and dilutive risks for shareholders.

Cogint (COGT) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogint (COGT) Forecast

Analysts have given Cogint (COGT) a Buy based on their latest research and market trends.

According to 10 analysts, Cogint (COGT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogint (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.